Get the Stockscreener App
108.33
0.42%
-0.46
After Hours:
108.44
0.11
+0.10%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $108.33, with a volume of 6.88M.
It is down -0.42% in the last 24 hours and up +2.72% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$108.79
Open:
$108.105
24h Volume:
6.88M
Relative Volume:
0.62
Market Cap:
$187.45B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
35.02
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
-3.68%
1M Performance:
+2.72%
6M Performance:
-4.22%
1Y Performance:
-18.43%
1-Day Range:
$107.36
$110.01
1-Week Range:
$107.36
$113.91
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Where Will SCHD Stock Be in 5 Years? - The Motley Fool
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - medtechdive.com
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
How Abbott Is Leaning Into RFK Jr.'s MAHA Movement - Investor's Business Daily
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends - 247wallst.com
Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US - marketscreener.com
No mixing: Similac's whole-milk formula launches at powder-like prices - Stock Titan
Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval - simplywall.st
Abbott wins CE mark for new LAA closure device - medtechdive.com
Abbott Laboratories agrees to $670M settlement over premature infant formula claims - Top Class Actions
Abbott Laboratories Obtains CE Mark for Amulet 360 LAA - Medical Device and Diagnostic industry
Lawsuit accusing Abbott MitraClip of kickbacks will proceed - Courthouse News
Analyst recommendations: Nvidia, Intuit, BofA, Abbott Laboratories, Google… - marketscreener.com
Why Is Abbott Laboratories (ABT) Launching A First Of Its Kind Diabetes Wearable? - simplywall.st
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott Labs Settles Investor Formula Recall Suit for $89 Million - Bloomberg Law News
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients - Yahoo
How Investors Are Reacting To Abbott Laboratories (ABT) US$670 Million NEC Settlement And Litigation Clarity - Yahoo Finance
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Exact Sciences stock enters new chapter after Abbott acquisition - Ad-hoc-news.de
Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com
Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance
Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian
True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC - MarketBeat
Capital Investment Advisory Services LLC Sells 12,335 Shares of Abbott Laboratories $ABT - MarketBeat
ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
1.15%
1.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):